Sphingosine kinase 2-deficiency mediated changes in spinal pain processing

Area of Science:

• Neuroscience
• Biochemistry
• Pain Research

Background:

• Chronic pain is a significant global health burden requiring novel therapeutic targets.
• Bioactive lipid sphingosine 1-phosphate (S1P) modulates nociceptive signaling.
• The specific role of S1P-generating enzymes, like sphingosine kinase 2 (Sphk2), in pain is largely unknown.

Purpose of the Study:

• To investigate the role of sphingosine kinase 2 (Sphk2) in nociception and chronic pain.
• To determine the expression of Sphk1 and Sphk2 in the spinal cord.
• To analyze the impact of Sphk2 deficiency on pain responses and central sensitization.

Main Methods:

• Utilized Sphk2-deficient (Sphk2(-/-)) and Sphk1-deficient (Sphk1(-/-)) mouse models.
• Measured spinal S1P levels.
• Assessed pain responses in acute inflammatory and chronic peripheral inflammation models.
• Analyzed gene expression (P2X4 receptor, BDNF, iNOS) and glial activation (Iba-1, GFAP) in the spinal cord.

Main Results:

• Sphk2(-/-) mice exhibited lower spinal S1P levels compared to wild-type.
• Sphk2 deficiency facilitated late-phase inflammatory pain and mechanical sensitivity in chronic inflammation.
• Sphk2(-/-) mice showed no increase in specific inflammatory markers or glial activation in the spinal cord following chronic inflammation.
• Sphk2 deficiency did not affect early acute pain responses or c-Fos expression.

Conclusions:

• Sphingosine kinase 2 (Sphk2) is implicated in the facilitation of nociceptive circuits within the central nervous system.
• Sphk2 appears critical for central sensitization and the formation of pain memory.
• Sphk2 represents a potential therapeutic target for managing chronic pain conditions.